Business
Hydreight Technologies Inc. Announces Closing of Oversubscribed $15 Million Bought Deal LIFE Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) ("Hydreight" or the "Company"), a leader in U.S. nationwide digital healthcare solutions, is pleased to announce that, further to the news release of the Company dated January 15, 2026, it has closed its previously announced "bought deal" private placement with Canaccord Gen
About this update from Hydreight Technologies Inc
[{"type":"text","content":"NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES","length":99,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) ("Hydreight" or the "Company"), a leader in U.S. nationwide digital healthcare solutions, is pleased to announce that, further to the news release of the Company dated January 15, 2026, it has closed its previously announced "bought deal" private placement with Canaccord Genuity Corp. (the "Lead Underwriter") as lead underwriter and sole bookrunner, and Beacon Securities Limited (together with the Lead Underwriter, the "Underwriters"). The Company issued 3,705,000 units of the Company (each, a "Unit") at a price of $4.05 per Unit for aggregate gross proceeds of $15,005,250 (the "Offering"). The Offering was conducted pursuant to an underwriting agreement dated January 27, 2026, between the Company and the Underwriters.","length":924,"tagName":"p"},{"type":"text","content":"Shane Madden, the Chief Executive Officer of the Company, commented:","length":68,"tagName":"p"},{"type":"text","content":"“This financing was oversubscribed within hours of announcement, reflecting strong conviction in Hydreight’s execution and the durability of our model. Q4 marked a clear inflection point for the business — expanding proven pharmacy product lines and launching high-demand products continued to drive real, scalable growth across all three verticals, and that momentum has carried decisively into 2026 with increasing visibility.","length":428,"tagName":"p"},{"type":"text","content":"The addition of multiple new high quality institutional investors at this stage meaningfully and strategically bolsters our share register while providing further validation of our platform and is an important step as we scale. With this additional capital, we are positioned to further accelerate customer growth by expanding our technology and platform offerings, increasing production capacity, accelerating new product rollouts, and strengthening the infrastructure required to support growing demand across our nationwide network. We believe these investments position the Company for another year of outsized, exponential gr...